Rezdiffra (Resmetirom) Safety in Young Adults (18-29)

Why Young Adults With MASH Need Specific Safety Guidance

MASH prevalence among adults aged 18-29 is rising in parallel with obesity rates. Data from the National Health and Nutrition Examination Survey (NHANES) 2017-2020 estimated that roughly 8-12% of U.S. adults aged 20-39 meet criteria for metabolic dysfunction-associated steatotic liver disease, the broader category that includes MASH. Diagnosing fibrotic MASH in this age group often happens incidentally through elevated ALT on routine labs or imaging ordered for other reasons.

Before resmetirom, no FDA-approved pharmacotherapy existed for MASH at any age. Young adults were left with lifestyle modification alone, sometimes for years, while fibrosis progressed silently. The approval of Rezdiffra changed that equation. But a 24-year-old starting a drug they may take for decades faces questions that a 58-year-old does not: thyroid axis suppression over a long horizon, family planning timing, interaction with oral contraceptives, and the simple reality that safety data beyond 54 weeks remains limited. Each of these deserves direct attention.

MAESTRO-NASH: What the Key Trial Showed

The MAESTRO-NASH trial randomized 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3 to resmetirom 80 mg, 100 mg, or placebo. The primary endpoints at week 52 were MASH resolution with no worsening of fibrosis and fibrosis improvement by at least one stage with no worsening of NAFLD Activity Score. Results were significant for both doses. Among patients receiving 100 mg, 29.9% achieved MASH resolution versus 9.7% on placebo, and 25.9% achieved fibrosis improvement versus 14.2% on placebo [1].

The trial enrolled adults aged 18 and older. The mean age was approximately 56 years. Madrigal Pharmaceuticals has not published a subgroup analysis isolating participants under 30. This is a common limitation in hepatology trials, where younger patients represent a minority of enrollees because advanced fibrosis is less prevalent before age 40. The FDA prescribing label does not include age-stratified adverse event tables for young adults specifically.

What this means practically: the safety data that led to approval are driven overwhelmingly by participants in their 40s through 60s. Prescribers treating an 18-29-year-old are extrapolating from that dataset. The mechanism of action (selective THR-beta agonism) has no known age-dependent pharmacodynamic difference, which supports reasonable extrapolation, but the absence of dedicated young-adult data should be disclosed in shared decision-making conversations.

Adverse Event Profile Relevant to Younger Patients

Across the MAESTRO-NASH 52-week cohort, the most frequent adverse events with resmetirom 100 mg versus placebo were diarrhea (27.0% vs. 14.6%), nausea (22.2% vs. 12.4%), and decreased appetite. Serious adverse events occurred at similar rates between resmetirom and placebo groups [1]. Treatment discontinuation due to adverse events was 5.4% with 100 mg versus 2.5% with placebo.

For young adults, GI side effects carry a distinct quality-of-life burden. This age group is more likely to be in workplace onboarding periods, attending university, or navigating social situations where unpredictable diarrhea creates real barriers to adherence. The prescribing information recommends taking resmetirom with food, which reduces GI symptoms. Timing the dose with the largest meal of the day is a practical strategy clinicians have adopted off-protocol.

Hepatotoxicity signals deserve mention. The Rezdiffra label carries a warning about potential for drug-induced liver injury, requiring ALT, AST, and bilirubin monitoring before initiation, during dose titration, and periodically thereafter. In MAESTRO-NASH, ALT reductions were actually a therapeutic benefit (mean ALT decreased by approximately 36% from baseline with 100 mg at week 52), but rare idiosyncratic liver injury remains a theoretical risk with any new hepatic drug [1]. Young adults, who may be less accustomed to regular lab monitoring, need clear instructions: bloodwork at baseline, 4 weeks, 8 weeks, 12 weeks, then every 3-6 months during the first two years.

Thyroid Hormone Axis: The Core Mechanistic Concern

Resmetirom is a selective agonist of thyroid hormone receptor beta, concentrated in the liver. It was designed to avoid activation of THR-alpha, which mediates cardiac and bone effects of thyroid hormone. This selectivity is the basis for its safety advantage over non-selective thyroid hormone analogs that were abandoned in earlier development due to bone loss and tachycardia [2].

In MAESTRO-NASH, TSH levels declined modestly with resmetirom, consistent with feedback suppression on the hypothalamic-pituitary-thyroid axis. Mean TSH reductions were approximately 30-40% from baseline, though values generally remained within the normal reference range. Free T4 levels also declined slightly. No clinical hypothyroidism or hyperthyroidism signals emerged in the trial [1].

The concern for young adults is duration. A 25-year-old may take this drug for 30+ years. Chronic TSH suppression, even within the normal range, over decades has no precedent with this mechanism. The MAESTRO-OUTCOMES trial, expected to report around 2028, will provide 54-month safety data, but even that falls far short of a lifetime exposure window. The Endocrine Society's guidelines on thyroid function monitoring recommend periodic assessment of thyroid function in patients on medications that affect the HPT axis, a principle that applies directly here.

Young adults with pre-existing thyroid conditions (Hashimoto's thyroiditis, Graves' disease in remission, subclinical hypothyroidism) require particular caution. These conditions are disproportionately common in women aged 18-29. No subgroup analysis of resmetirom in patients with baseline thyroid disease has been published, and the MAESTRO-NASH protocol excluded patients with uncontrolled thyroid dysfunction. Prescribers should obtain a full thyroid panel (TSH, free T4, TPO antibodies) before starting resmetirom in any young adult.

Fertility, Contraception, and Family Planning

The Rezdiffra prescribing information notes that adequate fertility studies in humans have not been conducted. Animal reproductive toxicology studies (conducted in rats and rabbits at supratherapeutic exposures) showed some evidence of developmental toxicity, including reduced fetal body weight, though these findings occurred at doses well above the human equivalent of 100 mg daily [3].

HealthRX Young-Adult Resmetirom Fertility Decision Framework

For clinicians and patients navigating resmetirom in the context of reproductive planning, consider this staged approach:

1. Pre-treatment (both sexes): Document baseline reproductive goals and anticipated timeline. If pregnancy is planned within 12 months, weigh whether deferring resmetirom initiation is appropriate given the fibrosis stage.
2. During treatment (women): Use effective contraception throughout. The prescribing information does not specify a washout period before conception, but resmetirom's half-life of approximately 40-50 hours suggests a 2-week drug-free interval would achieve negligible plasma levels. Coordinate with OB/GYN before planned discontinuation.
3. During treatment (men): No human spermatogenesis data exist for resmetirom. Animal studies did not reveal male fertility impairment at therapeutic-equivalent doses, but inform male patients of this data gap.
4. Breastfeeding: No human lactation data available. The molecular weight (approximately 530 Da) and high protein binding suggest limited transfer into breast milk, but absence of data means risk cannot be excluded.

This is particularly relevant for the 18-29 cohort because MASH treatment durations are indefinite. A 22-year-old starting Rezdiffra today who plans to have children at 28 needs a prospective plan for treatment interruption that balances liver disease progression against reproductive goals.

There are no published data on interactions between resmetirom and combined oral contraceptives or hormonal IUDs. Resmetirom is metabolized primarily by CYP2C8 and to a lesser extent CYP3A4. Ethinyl estradiol, found in many combined oral contraceptives, is also a CYP3A4 substrate, creating a theoretical interaction risk. Until formal drug-drug interaction studies address this, clinicians should monitor for breakthrough bleeding or reduced contraceptive efficacy and consider non-hormonal or progestin-only methods as alternatives [3].

Drug Interactions That Matter at This Age

Young adults take medications that older MASH populations typically do not. Several interaction categories deserve attention.

Hormonal contraceptives. As noted above, CYP3A4 overlap creates a theoretical concern. Pharmacokinetic interaction studies have not been completed for this pair.

SSRIs and SNRIs. Depression and anxiety treatment is common in the 18-29 age group. Resmetirom does not appear to inhibit CYP2D6, the primary metabolic pathway for most SSRIs (fluoxetine, paroxetine, sertraline). No clinically significant interactions have been reported, but co-prescription of drugs with hepatic metabolism warrants standard liver function monitoring [1].

Isotretinoin (Accutane). Occasionally co-prescribed in young adults treating severe acne. Both isotretinoin and resmetirom carry hepatotoxicity warnings. Concurrent use has not been studied, and combined liver injury risk would require more frequent ALT/AST monitoring, likely every 4 weeks during overlap.

Statins. The MAESTRO-NASH trial permitted statin use, and resmetirom itself reduced LDL cholesterol by approximately 14% at the 100 mg dose. For young adults already on statins for familial hypercholesterolemia or metabolic syndrome, this LDL-lowering effect is additive and could allow statin dose reduction, but changes should be guided by lipid panels rather than empiric adjustment [1].

Weight-Based Dosing and Body Composition in Young Adults

Rezdiffra uses a weight-based dosing threshold. Patients weighing less than 100 kg receive 80 mg daily; those at or above 100 kg receive 100 mg daily. In MAESTRO-NASH, both doses achieved significant histological improvement, though the 100 mg dose showed numerically higher response rates across endpoints [1].

Young adults have different body composition trajectories than middle-aged patients. A 26-year-old male at 98 kg who is actively gaining weight through muscle hypertrophy or continued metabolic syndrome progression may cross the 100 kg threshold during treatment. The prescribing information does not specify how often to reassess weight for dose adjustment. A practical approach: recheck weight at each lab monitoring visit and adjust dose if the patient crosses the threshold in either direction.

For young adults at the lower end of the BMI spectrum (MASH occurs in non-obese individuals at rates of approximately 10-20% of all MASH cases), the 80 mg dose applies. Lean MASH in young adults is an understudied phenotype overall, and these patients were underrepresented in MAESTRO-NASH.

Monitoring Protocol for the 18-29 Age Group

Combining the prescribing information requirements with age-specific considerations, a practical monitoring schedule looks like this:

Baseline (before first dose):

• Liver panel: ALT, AST, total bilirubin, alkaline phosphatase
• Thyroid panel: TSH, free T4, TPO antibodies
• Lipid panel: LDL, HDL, triglycerides, total cholesterol
• Pregnancy test (if applicable)
• Weight, documented reproductive goals, current medication list including OTC and supplements

Week 4 and Week 8:

• ALT, AST, bilirubin
• TSH, free T4
• Symptom check: GI tolerability, energy levels, mood

Week 12:

• Full liver panel
• Thyroid panel
• Lipid panel
• Weight reassessment for dose threshold

Every 6 months thereafter (years 1-2):

• Liver panel, thyroid function, lipid panel
• Reproductive planning reassessment
• FibroScan or equivalent non-invasive fibrosis assessment annually

After year 2:

• Monitoring frequency may extend to every 6-12 months if labs are stable
• Annual thyroid function testing should continue indefinitely given the mechanism of action

The American Association for the Study of Liver Diseases (AASLD) practice guidance on MASLD recommends non-invasive fibrosis monitoring for all patients on pharmacotherapy for MASH, with serial FibroScan or FIB-4 to track treatment response and inform continuation decisions.

Long-Term Unknowns: What Resmetirom's Accelerated Approval Means

Rezdiffra was approved via the FDA's accelerated approval pathway, which permits marketing based on a surrogate endpoint (histological improvement) reasonably likely to predict clinical benefit (reduced progression to cirrhosis, liver failure, or death). The confirmatory trial, MAESTRO-OUTCOMES, is a cardiovascular and liver outcomes study that Madrigal Pharmaceuticals expects to complete around 2028 [1].

This means that as of mid-2026, no hard clinical outcome data (transplant-free survival, cardiovascular events, hepatocellular carcinoma incidence) exist for resmetirom. For a 55-year-old with F3 fibrosis, the risk-benefit calculus of starting therapy based on histological data is straightforward. For a 23-year-old with F2 fibrosis, the calculus requires acknowledging that the drug may be taken for decades based on 52 weeks of biopsy data.

The FDA's 2024 approval letter explicitly notes that continued approval may be contingent on verification of clinical benefit in confirmatory trials. Young adults starting resmetirom should be counseled that the evidence base is still maturing and that treatment decisions may need revision as MAESTRO-OUTCOMES results emerge.

When to Start, When to Wait

Not every young adult with MASH needs resmetirom immediately. The FDA indication is specific: non-cirrhotic MASH with moderate to advanced hepatic fibrosis (F2-F3). Young adults with stage F0-F1 fibrosis are not candidates under the current label, regardless of NASH Activity Score.

For eligible young adults (biopsy-confirmed F2-F3), the decision depends on the pace of disease progression. A patient whose fibrosis advanced from F1 to F2 over 3-5 years on serial biopsy or elastography has demonstrated progressive disease and has a stronger case for pharmacotherapy. A patient identified at F2 on a single biopsy without prior data may benefit from 6-12 months of intensive lifestyle modification with repeat assessment before committing to indefinite drug therapy.

The AASLD practice guidance supports lifestyle intervention as the foundation of MASH management at all fibrosis stages, with pharmacotherapy reserved for patients with significant fibrosis (F2 or greater) who have not achieved adequate response to behavioral changes. For a young adult, "adequate response" should include documented attempts at sustained dietary modification and 150+ minutes per week of moderate-intensity exercise over at least 6 months, with objective endpoints (ALT normalization, 7-10% total body weight loss, or fibrosis regression on elastography).

Resmetirom 100 mg daily reduced mean LDL cholesterol by 13.6% at 52 weeks in MAESTRO-NASH, which may provide ancillary cardiovascular benefit in young adults with metabolic syndrome [1].